Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term 951-77-9 (Deoxycytidine). Found 5 abstracts

Lauritsen JP, Haks MC, Lefebvre JM, Kappes DJ, Wiest DL, Chen X, Arciero CA, Godwin AK, Barsevick AM, Whitmer K, Nail LM, Beck SL, Dudley WN, Weiner LM, Treat J. Role of the transcription factor Th-POK in CD4:CD8 lineage commitment. . Immunological reviews. 2006 Feb;209(2):237-52.
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.[see comment]. Journal of Clinical Oncology. 2006 Sep;24(25):4069-77.
Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 2005 May;15 Suppl 1:12-7.
Langer CJ. Irinotecan in advanced lung cancer: focus on North American trials. Oncology (Huntington). 2004 Jun;18(7 Suppl 4):17-28.
Sasson AR, Wetherington RW, Hoffman JP, Ross EA, Cooper H, Meropol NJ, Freedman G, Pingpank JF, Eisenberg BL. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. International Journal of Gastrointestinal Cancer. 2003 Jan;34(2-3):121-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term 951-77-9 (Deoxycytidine)

951-77-9 (Deoxycytidine) dt [Drug Therapy] aa [Analogs & Derivatives] 103882-84-4 (gemcitabine) Deoxycytidine ad [Administration & Dosage] Antineoplastic Combined Chemotherapy Protocols Female 0 (Antineoplastic Combined Chemotherapy Protocols) [Therapeutic Use] Non-US Gov't Research Support Lung Neoplasms Middle Aged 100286-90-6 (irinotecan) pa [Pathology] Fluorouracil 7689-03-4 (Camptothecin) 51-21-8 (Fluorouracil) Aged Antineoplastic) 0 (Antimetabolites Male Adult Survival Analysis 15663-27-1 (Cisplatin) 80 and over Aged me [Metabolism] tu [Therapeutic Use] Antineoplastic Antimetabolites Camptothecin tu Pancreatic Neoplasms ai [Antagonists & Inhibitors] Taxoids drug therapy MH - Cisplatin isolation & purification rt [Radiotherapy] 53643-48-4 (Vindesine) en [Enzymology] 50-07-7 (Mitomycin) Fibrosis Transgenic Mice et [Etiology] Reverse Transcriptase Polymerase Chain Reaction Dihydrouracil Dehydrogenase (NADP) Treatment Outcome therapeutic 33419-42-0 (Etoposide) su [Surgery] Feasibility Studies Phosphorylation EC 1-3-1-2 (Dihydrouracil Dehydrogenase (NADP)) methods Neoplastic Gene Expression Regulation Adenocarcinoma EC 1-17-4 (Ribonucleotide Reductases) Comparative Study Monoclonal Antibodies ge [Genetics] tu [Therapeutic Neoadjuvant Therapy therapeutic use MH - Antineoplastic Combined Chemotherapy Protocols Thymidine Phosphorylase Retrospective Studies Human Enzymologic Gene Expression Regulation Colorectal Neoplasms Phytogenic Antineoplastic Agents Predictive Value of Tests North America Antineoplastic Agents Genetic Engineering Phenotype Ribonucleotide Reductases Ovarian Neoplasms 154361-50-9 (capecitabine) pd [Pharmacology] Neoplasm DNA EC 2-4-2-4 (Thymidine Phosphorylase) ch [Chemistry] Phytogenic) 0 (Antineoplastic Agents Biological) 0 (Tumor Markers immunology Thymidylate Synthase Effects] therapeutic use MH - Clinical Tr Non-US Gov't Support Small Cell Carcinoma 0 (Taxoids) Multiple Drug Resistance ae [Adverse EC 2-1-1-45 (Thymidylate Synthase) Monoclonal) 0 (Antibodies Neoplasm) 0 (DNA Cisplatin Mitomycin Biological Tumor Markers Non-Small-Cell Lung therapeutic use MH - Carcinoma Disease-Free Survival 0 (Antineoplastic Agents) Local Neoplasm Recurrence 0 (bevacizumab) Etoposide drug therapy Type I DNA Topoisomerases Neoplasm Staging NIH Research Support-Extramural Survival Rate Vindesine 0 (Enzyme Inhibitors) administration & dosage Use] Non-Small-Cell Lung Carcinoma Mice Adjuvant Radiotherapy Pancreatectomy Immunohistochemistry use Type I) EC 5-99-1-2 (DNA Topoisomerases Proportional Hazards Models Logistic Models Enzyme Inhibitors
Last updated on Wednesday, February 05, 2020